• All
  • Important
  • Financial Update
  • Fund Raise
  • Board Meeting
  • Dividend/Bonus
  • JV/Acquisition
  • Investor Meet
  • Insider Trade
  • Pledging
  • Others
    ALPHA TRIBE

    Aurobindo Pharma Limited — Updates, 06-04-2026: Press Release

    06-04-2026 | 04:02 pm

    Aurobindo's subsidiary, CuraTeQ Biologics, announced positive Phase 3 results for biosimilar BP11 (omalizumab). The study met all primary endpoints, showing high comparability to Xolair, supporting regulatory submissions for multiple indications. This paves the way for market access.

    No comments yet. Be the first to comment!

    All announcements from Aurobindo Pharma Limited